Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care

This study has been terminated.

First Received: March 15, 2006 No Changes Posted

Sponsored by:	University Hospital, Geneva
Information provided by:	University Hospital, Geneva
ClinicalTrials.gov Identifier:	NCT00303407

Purpose

To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care

Condition	Intervention	Phase
Cancer Venous Thromboembolism	Drug: nadroparin	Phase IV

MedlinePlus related topics: Cancer Palliative Care

U.S. FDA Resources

Study Type:	Observational
Study Design:	Longitudinal, Defined Population, Prospective Study

Further study details as provided by University Hospital, Geneva:

Study Start Date:	January 2001
Estimated Study Completion Date:	July 2002

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Cancer patients in palliative care
Patients fully informed about their condition
Signed informed consent
No exclusion criteria

Exclusion Criteria:

Absence of advanced cancer
Cancer previously cured
Venous thromboembolism diagnosed within 6 months prior to inclusion
Absence of discerning capacity
Active anti-thrombotic treatment with heparins or coumarines
Thrombocytopenia <50G/l
PTT >45sec
TP<35%
Active bleeding
Renal failure <20ml/min
Past history of heparin-induced thrombocytopenia

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00303407

Locations

Switzerland, Geneva
Center of Continuous Care, chemin de la Savonnière
Collonge-Bellerive (Geneva), Geneva, Switzerland, 1245

Sponsors and Collaborators

University Hospital, Geneva

Investigators

Principal Investigator:

Catherine Weber, MD

Center of Continuous Care, chemin de la Savonnière 11, CH-1245 Collonge-Bellerive

More Information

Publications:

Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost. 1997 Jul;78(1):141-4. Review.

Study ID Numbers:	SPOT 99/54
Study First Received:	March 15, 2006
Last Updated:	March 15, 2006
ClinicalTrials.gov Identifier:	NCT00303407 History of Changes
Health Authority:	Switzerland: Ethikkommission

Study placed in the following topic categories:

Fibrin Modulating Agents
Embolism and Thrombosis
Anticoagulants
Nadroparin
Embolism
Vascular Diseases

Fibrinolytic Agents
Cardiovascular Agents
Venous Thromboembolism
Thrombosis
Thromboembolism

Additional relevant MeSH terms:

Nadroparin
Anticoagulants
Molecular Mechanisms of Pharmacological Action
Hematologic Agents
Vascular Diseases
Fibrinolytic Agents
Cardiovascular Agents
Venous Thromboembolism

Thromboembolism
Thrombosis
Pharmacologic Actions
Embolism and Thrombosis
Fibrin Modulating Agents
Therapeutic Uses
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 07, 2009